Manufacturing: Page 14
-
Bluebird gets European green light for gene therapy production
Although Bluebird won EU approval for Zynteglo in June, the biotech delayed launching the one-time treatment to finalize manufacturing specifications.
By Kristin Jensen • Oct. 24, 2019 -
GSK hands 2 of its less profitable vaccines to Bavarian Nordic
The deal, worth about $335 million upfront, will help GSK simplify its supply chain and allow it to reinvest in higher growth areas, according to the company.
By Jacob Bell • Oct. 21, 2019 -
FDA warns losartan manufacturer of violations at Indian plant
The agency faulted Torrent Pharmaceuticals' executive oversight in a warning letter issued after the company voluntarily recalled lots of the antihypertensive.
By Kristin Jensen • Oct. 17, 2019 -
Courtesy of Sanofi
Sanofi upgrades biotech manufacturing with new Massachusetts plant
The French pharma has spent about $320 million over the past five years on the facility, part of a broader effort to retool how it makes the drugs it sells.
By Andrew Dunn • Oct. 15, 2019 -
Lilly shuttering UK neuroscience research site
Most employees will be relocated to a new facility in the area, although Lilly expects to lay off as many as 80 workers.
By Jonathan Gardner • Oct. 15, 2019 -
Sponsored by MilliporeSigma
Product characterization: Reveal your molecule earlier, faster, and with accuracy
Partnering for product characterization can streamline drug development and create efficiencies in moving from concept to clinic.
Oct. 15, 2019 -
Sponsored by MilliporeSigma
Product characterization: Reveal your molecule earlier, faster, and with accuracy
Partnering for product characterization can streamline drug development and create efficiencies in moving from concept to clinic.
Oct. 15, 2019 -
Gene therapy biotechs caught in manufacturing crunch
Rising demand for contract manufacturing services could push companies to invest more in their own capabilities despite the high cost.
By Ned Pagliarulo • Updated Oct. 11, 2019 -
Premier joins forces with Amphastar on 7 drugs in short supply
The agreement is another example of how healthcare companies are searching for new ways to address drug shortages.
By Kristin Jensen • Oct. 10, 2019 -
Cellectis turns to Lonza to manufacture cancer cell therapies
Lonza's Netherlands facility will complement Cellectis' own sites in development, the French biopharma said.
By Kristin Jensen • Oct. 3, 2019 -
FDA calls generic Zantac carcinogen levels 'unacceptable,' but pushes back against lab claims
Regulators say the third-party lab isn't using a suitable method in tests showing even higher levels of NDMA, a probable human carcinogen.
By Kristin Jensen • Oct. 3, 2019 -
After fanfare, Civica Rx delivers its 1st drugs
A Utah hospital was the first recipient of a medication produced by the hospital coalition, which set out last year to provide generics typically in short supply.
By Samantha Liss • Oct. 2, 2019 -
CVS suspends Zantac sales, as recalls widen over carcinogen fears
Citing an "abundance of caution," CVS announced it would halt sales of the commonly used heartburn drug until further notice.
By Andrew Dunn • Sept. 30, 2019 -
Novartis recall of generic Zantac expands to US
British drugmaker GlaxoSmithKline, meanwhile, said it would halt distribution of Zantac product in countries where it sells the heartburn drug.
By Kristin Jensen • Sept. 26, 2019 -
GSK to spend $120M on new manufacturing hub for drug pipeline
The investment is part of nearly $400 million the British pharma has spent since 2017 to build out its vaccine and specialty drug production in the U.S.
By Kristin Jensen • Sept. 26, 2019 -
FDA
Novartis stops distributing generic Zantac as carcinogen concerns rise
While the FDA continues to investigate NDMA contamination in generic Zantac, Canadian regulators moved to halt distribution of the heartburn drug.
By Kristin Jensen • Sept. 19, 2019 -
Private equity firm to buy Sanofi's oldest plant in India
Advent International snagged Sanofi's generics unit for $2 billion last year. Now, that unit is ready to acquire the Indian plant for about $37 million.
By Kristin Jensen • Sept. 12, 2019 -
Mallinckrodt selling CDMO business for up to $250M
The deal gives needed cash to Mallinckrodt, which is under pressure for its role in the opioid epidemic, and provides another example of private equity's interest in contract manufacturing.
By Kristin Jensen • Sept. 12, 2019 -
Latest Civica Rx pact aims to ease shortage of emergency medicine
The Intermountain-led coalition of providers inked a deal with Exela for supplying sodium bicarbonate to member hospitals.
By Samantha Liss • Sept. 10, 2019 -
Sponsored by Millipore Sigma
How to get upstream right the first time while accelerating the time from DNA to material?
BioReliance's mini-pool approach enables efficient selection of high producing cell lines and accelerates upstream processes.
Sept. 6, 2019 -
Celltrion taps Lonza to produce some of its Remicade biosimilar
Under the deal, Lonza will make Remsima drug substance at its commercial facility in Singapore to cover European and North American markets.
By Jacob Bell • Sept. 5, 2019 -
Novo Nordisk Foundation makes green grant to Danish-US university collaboration
The $27 million grant will fund a five-year program in biopharmaceutical manufacturing, run in partnership by NC State and the Technical University of Denmark.
By Jonathan Gardner • Sept. 5, 2019 -
Elizabeth Regan/BioPharma Dive
Catalent's legacy business outshined by acquisitions
The recent additions of Cook Pharmica, Juniper and Paragon are driving more revenue growth than the contract manufacturer's base business.
By Jacob Bell • Aug. 29, 2019 -
Biopharma jobs boom in Massachusetts, though challenges still exist
Many more jobs have opened up in R&D than in manufacturing, which saw growth of just 1% between 2017 and 2018.
By Jacob Bell • Aug. 27, 2019 -
HHS to fund further manufacturing of Merck Ebola vaccine
An outbreak of the virus in the Democratic Republic of the Congo is now the second largest on record, making vaccination programs more critical.
By Ned Pagliarulo • Aug. 22, 2019
Previous
